Radical Decision from Donald Trump in the Pharmaceutical Industry: 100% Customs Duty on Generic Medicines as of 2028

United States President Donald Trump shared with the public a new economic policy move that will radically change the healthcare and pharmaceutical industry. According to the official statement made on Tuesday, a 100% customs duty will be imposed on generic drugs imported into the USA as of August 2028. This radical step is considered one of the most concrete reflections of Washington's strategy to increase domestic production capacity and minimize foreign dependency.

What happened?

This new regulation, announced by President Trump, started a major debate around the world, especially regarding access to affordable medicines. The 100% tariff aims to theoretically double the cost of generic drugs, making imports of these products economically unsustainable. It is predicted that with this move, the government will force pharmaceutical companies to move their production facilities to US territory, thereby encouraging the production of 'American-made' drugs.

The tax regulation in question covers not only certain countries, but all global suppliers that have a share in the generic drug market. Although the transition period until 2028 offers pharmaceutical companies a window to review their production strategies, industry representatives are concerned about whether this period is sufficient to move or establish huge production facilities. The source text did not contain detailed information about the technical details or whether there were exemptions for the implementation of this decision.

Background

The USA has been largely foreign-dependent in its pharmaceutical supply chain for many years. In particular, most of the generic drugs are supplied from centers in Asia and Europe due to low production costs. The Trump administration describes this dependence as a risk to national security and economic sovereignty. The supply chain breaks experienced during the pandemic period further increased the importance of domestic production in Washington.

This decision is read as a version of Trump's 'America First' doctrine adapted to the healthcare sector. The extension of protectionist customs policies, which were previously implemented in sectors such as automotive and steel, to the pharmaceutical industry, which now has strategic importance, is considered an indicator of the hardening of the US's global trade policies. The pharmaceutical industry is known for having a more sensitive structure than other sectors due to high R&D costs and complex logistics processes.

Why is it important?

The most direct impact of this regulation will be seen in the cost of access to medications for the American consumer. Generic drugs form the backbone of the healthcare system because they are more affordable alternatives to drugs whose patents have expired. If a 100% tax is imposed on these imported drugs, it seems inevitable that this situation will be directly reflected in the prices on pharmacy shelves. This may make it difficult for low-income citizens to access health services.

On the other hand, this situation is seen as a great opportunity for domestic pharmaceutical manufacturers. US-based pharmaceutical companies can increase their market shares by gaining a competitive advantage. However, whether domestic production can meet the increasing demand in such a short time and keep prices balanced is a matter of serious debate among economists. Additionally, the possibility of other countries retaliating against this decision brings with it the risk of a global trade war.

What do experts and parties say?

The source text did not include any direct quotes from pharmaceutical industry representatives or health policy experts regarding this decision. However, general market reactions are that such protectionist measures may create uncertainty in the markets in the short term. International trade analysts predict that legal processes may begin regarding the compliance of this decision with the World Trade Organization (WTO) rules.

What to watch next?

In the coming period, the steps taken by pharmaceutical companies to move their production facilities to the USA will be closely monitored. Additionally, it is a matter of curiosity whether Congress will make a legal regulation against this decision or whether tax rates will be relaxed under the pressure of health lobbies. In the period until 2028, fluctuations in drug prices and possible disruptions in the supply chain will continue to be the main agenda item of the global health economy.